Ganne-Carrié N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, Dény P, Trinchet J C, Callard P, Guettier C, Beaugrand M
Service d'Hépato-Gastroentérologie, Hôpital Jean Verdier, Cedex, France.
Hepatology. 1996 May;23(5):1112-8. doi: 10.1002/hep.510230527.
The aim of this study was to identify high-risk patients for hepatocellular carcinoma (HCC). Among 151 patients with histologically proven cirrhosis hospitalized from 1987 to 1990 and prospectively followed-up until June 1994, 31 developed HCC. We assessed the predictive value of 22 variables recorded at enrollment for HCC occurrence by the log rank test and the Cox proportional hazards model. Six clinical and biological variables summarized predictive information of HCC: age > or = 50 years (P = .01), male (P = .01), large esophageal varices (EV) (P = .03), prothrombin activity < 70% (P = .04), serum alpha-fetoprotein (AFP) > or = 15 ng/L (P = .06), and anti-hepatitis C virus antibodies (P = .08). A clinicobiological predictive score identified two groups of patients at low (n = 67; 3-year cumulative incidence, 0%) and high risk for HCC (n = 84; 3-year cumulative incidence, 24%). The predictive value of this score was confirmed using an independent population of 49 patients with cirrhosis. Furthermore, liver large-cell dysplasia (LCD) had an additional predictive value in high-risk patients (P = 10(-4), which thus helped to define a subgroup at very high risk for HCC (n = 12; 3-year cumulative incidence, 72%). In Western patients with cirrhosis, a limited number of usual variables can identify a group of patients at high risk for HCC. Among these patients, liver biopsy allows for the determination a subgroup of patients at very high risk for HCC requiring intensive screening or preventive measures.
本研究的目的是识别肝细胞癌(HCC)的高危患者。在1987年至1990年住院的151例经组织学证实为肝硬化的患者中,并对其进行前瞻性随访直至1994年6月,其中31例发生了HCC。我们通过对数秩检验和Cox比例风险模型评估了入组时记录的22个变量对HCC发生的预测价值。六个临床和生物学变量总结了HCC的预测信息:年龄≥50岁(P = 0.01)、男性(P = 0.01)、大食管静脉曲张(EV)(P = 0.03)、凝血酶原活性<70%(P = 0.04)、血清甲胎蛋白(AFP)≥15 ng/L(P = 0.06)以及抗丙型肝炎病毒抗体(P = 0.08)。一个临床生物学预测评分确定了两组HCC低风险患者(n = 67;3年累积发病率,0%)和高风险患者(n = 84;3年累积发病率,24%)。使用49例肝硬化患者的独立人群证实了该评分的预测价值。此外,肝大细胞发育异常(LCD)在高危患者中具有额外的预测价值(P = 10⁻⁴),这有助于定义一组HCC极高风险患者(n = 12;3年累积发病率,72%)。在西方肝硬化患者中,有限数量的常见变量可以识别出一组HCC高危患者。在这些患者中,肝活检可以确定一组HCC极高风险患者,需要进行强化筛查或预防措施。